These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 6203820

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Diffuse thymus hyperplasia following chemotherapy for nodular sclerosing Hodgkin lymphoma].
    Hermann R, Greminger P, Dommann-Scherrer C, Krestin GP, Stahel R.
    Schweiz Med Wochenschr; 1994 Sep 24; 124(38):1666-71. PubMed ID: 7524146
    [Abstract] [Full Text] [Related]

  • 24. [Cytostatic chemotherapy of lymphogranulomatosis].
    Dold U.
    Dtsch Med Wochenschr; 1978 Feb 10; 103(6):235-8. PubMed ID: 75085
    [No Abstract] [Full Text] [Related]

  • 25. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB).
    Wiernik PH, Schiffer CA.
    J Cancer Res Clin Oncol; 1988 Feb 10; 114(1):105-7. PubMed ID: 2450876
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Avascular necrosis of the femoral head after treatment of Hodgkin's disease.
    Tombolini V, Capua A, Pompili E.
    Acta Oncol; 1992 Feb 10; 31(1):64-5. PubMed ID: 1375043
    [No Abstract] [Full Text] [Related]

  • 28. [The practice of chemotherapy with the DeVita protocol].
    Gassmann W, Schmitz N, Löffler H.
    Dtsch Med Wochenschr; 1982 Jul 09; 107(27):1063-9. PubMed ID: 6177488
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].
    Osieka R, Bruntsch U, Gallmeier WM, Seeber S, Schmidt CG.
    Dtsch Med Wochenschr; 1976 Aug 06; 101(32):1177-82. PubMed ID: 59661
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The treatment of advanced hodgkin's disease.
    Straus DJ, Lee BJ, Koziner B, Nisce LZ, Young CW, Clarkson BD.
    Blut; 1981 Aug 06; 43(2):119-24. PubMed ID: 6167303
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
    Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD.
    Cancer; 2002 Dec 15; 95(12):2534-8. PubMed ID: 12467067
    [Abstract] [Full Text] [Related]

  • 36. Development of effective salvage treatment programs for Hodgkin's disease: an ongoing clinical challenge.
    Hoppe RT.
    Blood; 1991 May 15; 77(10):2093-5. PubMed ID: 1709367
    [No Abstract] [Full Text] [Related]

  • 37. MOPP, ABVD, or both to treat Hodgkin's disease.
    Aisenberg AC.
    N Engl J Med; 1993 Apr 08; 328(14):1045; author reply 1045-6. PubMed ID: 7680765
    [No Abstract] [Full Text] [Related]

  • 38. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.
    Bonadonna G, Zucali R, De Lena M, Valagussa P.
    Cancer Treat Rep; 1977 Aug 08; 61(5):769-77. PubMed ID: 70270
    [No Abstract] [Full Text] [Related]

  • 39. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
    Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY.
    Ai Zheng; 2006 Apr 08; 25(4):471-5. PubMed ID: 16613683
    [Abstract] [Full Text] [Related]

  • 40. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.